This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts' Actions: GM DVA RIG STI ABT URBN


Abbott Laboratories (ABT - Get Report) rated new Buy at Stifel. $40 price target. Company can generate solid and consistent earnings growth.

Atmel (ATML) upgraded at Craig-Hallum from Hold to Buy, Craig-Hallum said. $9 price target. Market conditions are improving and the company will likely score some big content wins.

Progressive Waste Solutions (BIN) upgraded to hold at TheStreet Ratings.

Coca-Cola Hellenic Bottling Company (CCH) downgraded to hold at TheStreet Ratings.

Comerica (CMA - Get Report) downgraded at Citigroup to Sell from Neutral. $31 price target. Valuation stretched.

Centurylink (CTL) downgraded at DA Davidson from Neutral to Underperform, DA Davidson said. $30 price target. Company cut its dividend and may see future dilution.

Davita (DVA - Get Report) downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Valuation call, as the stock is up 67% over the past 14 months. $120 price target.

EnCana (ECA - Get Report) downgraded at UBS to Neutral from Buy, UBS said. $21 price target. No longer expect a shift in strategy.

General Motors (GM - Get Report) downgraded at Craig-Hallum from Buy to Hold, Craig-Hallum said. Company lacks near-term catalysts. $30 price target.

Generac (GNRC) downgraded at Goldman from Neutral to Sell, Goldman Sachs said. Expect organic sales growth to slow down. $29 price target.

Generac upgraded at Stifel. GNRC was upgraded from Hold to Buy, Stifel Nicolaus said. $42 price target. Stock is attractive, following a post-earnings selloff.

Huntington Bancshares (HBAN) downgraded at Citigroup to Neutral from Buy, Citigroup said. $7.25 price target. Valuation call.

Netgear (NTGR) upgraded at Sterne Agee from Neutral to Buy, Sterne Agee said. $41 price target. Company has multiple potential growth drivers for the second half of the year.

Northwestern (NWE) downgraded at Wells from Outperform to Market Perform, Wells Fargo said. Valuation call.

Oceaneering (OII) downgraded at BMO to Market Perform, BMO Capital said. Valuation call, based on a $62 price target.

Pioneer Natural (PXD) downgraded at Canaccord to Sell, Canaccord Genuity said.Valuation call, based on a $113 price target.

QEP Resources (QEP) upgraded at Sterne Agee from to Neutral, Sterne Agee said. Outlook appears more balanced ahead of earnings.

Transocean (RIG) downgraded at Deutsche from Hold to Sell, Deutsche Bank said. $49 price target. Fleet downtime is increasing.

SunTrust Banks (STI) downgraded at Jefferies to Hold from Buy, Jefferies said. $30 price target. Revenue trajectory concerns.

Triumph (TGI) rated new Outperform at Wells. Company should see volume growth from new programs.

Urban Outfitters (URBN) downgraded at BMO from Outperform to Market Perform, BMO Capital said. $45 price target. Anthropologie turnaround is lagging.


Alexion Pharmaceuticals (ALXN) numbers lowered at Jefferies. Shares of ALXN now seen reaching $88, Jefferies said. Estimates also lowered on delay in Soliris launch. Hold rating.

Alpha Natural (ANR) numbers increased at Credit Suisse. ANR estimates were raised through 2014, Credit Suisse said. Company is cutting cash costs. Neutral rating and new $10 price target.

Discovery (DISCA) estimates, target reduced at Lazard. DISCA estimates were raised through 2014, Lazard Capital Markets said. Company is facing a higher tax rate. Buy rating and new $90 price target.

EOG Resources (EOG) target raised at Jefferies to EOG now seen reaching $155, Jefferies said. Higher Eagle Ford potential. Buy rating.

Generac (GNRC) numbers raised at Oppenheimer. Shares of GNRC now seen reaching $44, Oppenheimer said. Estimates also raised on positive outweighing the negatives. Outperform rating.

Incyte Corp (INCY) numbers lowered at Jefferies. Shares of INCY now seen reaching $36, Jefferies said. Estimates also lowered on guidance take down. Buy rating.

Pharmacyclics (PCYC) estimates, target raised at Credit Suisse. Shares of PCYC now seen reaching $90, accoridng to Credit Suisse. Estimates also increased, as Ibrutinib should drive growth. Outperform rating.

Pepsi (PEP) estimates, target boosted at Morgan Stanley. Shares of PEP now seen reaching $81, according to Morgan Stanley. Estimates also raised, given higher organic sales growth. Overweight rating.

Qlik Technologies (QLIK) numbers raised at Jefferies. Shares of QLIK now seen reaching $28, Jefferies said. Estimates also lowered on higher license expectations. Hold rating.

TAL International Group (TAL) target raised at Jefferies to $46, Jefferies said. Residual value drives earnings beat. Hold rating.

>To submit a news tip, email:


Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABT $37.97 -1.38%
CMA $42.28 0.00%
DVA $75.70 -0.17%
ECA $6.23 -0.95%
GM $30.96 1.38%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs